Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma

Launched by JIAN GUAN · Nov 15, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called Tranilast to help make radiotherapy (a common treatment for nasopharyngeal carcinoma, a type of head and neck cancer) more effective for patients whose cancer has come back after previous treatment. Researchers have found that Tranilast may help reduce the cancer's resistance to radiation, which could improve treatment outcomes. The trial aims to see how well Tranilast works in combination with radiotherapy for patients with recurrent nasopharyngeal carcinoma.

To participate, individuals must be at least 18 years old, have a confirmed diagnosis of recurrent nasopharyngeal carcinoma, and have already received standard treatments like surgery, chemotherapy, or radiotherapy. They also need to be in good health, with functioning organs, and must be willing to take the medication. Participants will receive Tranilast alongside their radiotherapy and will be closely monitored for safety and effectiveness. It's important to know that this trial is currently recruiting patients, and interested individuals should discuss with their healthcare provider to see if they might be a good fit.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Sign informed consent
• • 2. At least 18 years old on the date of signing the informed consent
• • 3. Previously received standard radical radiotherapy and chemotherapy
• • 4. Recurrent nasopharyngeal carcinoma in situ or cervical lymph nodes confirmed by pathological biopsy and imaging examination
• • 5. After multidisciplinary consultation, there was a clear indication for surgery, and the patient was informed and refused to accept surgical treatment 6）ECOG PS：0/1
• • 7) Laboratory examination confirmed good organ function, which should be carried out within 10 days before the first treatment.
• Exclusion Criteria:
• • 1. After evaluation, it does not meet the indications of re-radiotherapy
• • 2. unable to take oral medication
• • 3. Pregnancy or lactation
• • 4. Known allergy to Tranilast
• • 5. Patients who are judged by the researcher as unsuitable to participate in this trial